Latest Oxaliplatin Stories
NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer.
TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd.
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that VectibixÂ® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding...
PARIS and TARRYTOWN, N.Y., June 6, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.
A new study shows a combination treatment might be better than the drug gemcitabine at improving survival among patients with pancreatic cancer that has spread to other areas of the body.
PARIS and TARRYTOWN, N.Y., April 26, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.
THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). Amgen believes that Vectibix in combination with chemotherapy provides an important...
THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(Â®) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer...
CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.